ArticleHaematologica2019

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Miroslav Boudny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.